Cyclacel Pharmaceuticals Files 8-K on Financials
Ticker: BGMSP · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1130166
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cyclacel dropped an 8-K on financials, check it out.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Berkeley Heights, NJ.
Why It Matters
This filing provides investors with an update on Cyclacel Pharmaceuticals' financial performance and operational status, which is crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain any new material events or significant risk factors.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- August 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Berkeley Heights, NJ (location) — Principal executive office address
FAQ
What is the purpose of this Form 8-K filing?
The purpose of this Form 8-K filing is to report on the Results of Operations and Financial Condition of Cyclacel Pharmaceuticals, Inc., and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 14, 2024.
In which state is Cyclacel Pharmaceuticals, Inc. incorporated?
Cyclacel Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive address of Cyclacel Pharmaceuticals, Inc.?
The principal executive address of Cyclacel Pharmaceuticals, Inc. is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
What is the IRS Employer Identification Number for Cyclacel Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Cyclacel Pharmaceuticals, Inc. is 91-1707622.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-14 16:15:29
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
Filing Documents
- tm2421702d1_8k.htm (8-K) — 28KB
- tm2421702d1_ex99-1.htm (EX-99.1) — 49KB
- tm2421702d1_ex99-1img01.jpg (GRAPHIC) — 3KB
- tm2421702d1_ex99-1img02.jpg (GRAPHIC) — 2KB
- 0001104659-24-089636.txt ( ) — 306KB
- cycc-20240814.xsd (EX-101.SCH) — 3KB
- cycc-20240814_def.xml (EX-101.DEF) — 26KB
- cycc-20240814_lab.xml (EX-101.LAB) — 36KB
- cycc-20240814_pre.xml (EX-101.PRE) — 25KB
- tm2421702d1_8k_htm.xml (XML) — 5KB
02 Results
Item 2.02 Results of Operations and Financial Condition. The information set forth under this "Item 2.02. Results of Operations and Financial Condition," including the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Attached as Exhibit 99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the " Company "), dated August 14, 2024, announcing certain financial results for the second quarter ended June 30, 2024. The Company will conduct a conference call to review its financial results on August 14, 2024, at 4:30 p.m., Eastern Time.
01. Financial
Item 9.01. Financial (d) Exhibits. Exhibit No. Exhibit 99.1 Press release announcing financial results for the second quarter ended June 30, 2024, dated August 14, 2024. 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: August 14, 2024